Reshaping the future of nanopharmaceuticals: Ad iudicium

ACS Nano

Volumn 5, Issue 11, 2011, Pages 8454-8458

  Moghimi, S Moein ^a   Peer, Dan ^b   Langer, Robert ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TEL AVIV UNIVERSITY   (Israel)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPHARMACEUTICALS;

NANOTECHNOLOGY;

ENGINEERING;

BIOLOGY; DRUG DEVELOPMENT; ECONOMICS; HUMAN; NANOMEDICINE; PERSONALIZED MEDICINE; REVIEW; RISK;

BIOLOGY; DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; NANOMEDICINE; RISK;

EID: 81855218204     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn2038252     Document Type: Review

References (29)

1. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Nanomedicine: Current Progress and Future Prospects FASEB J. 2005, 19, 311-330 (Pubitemid 40316520)
2. Allen, T. M.; Cullis, P. R. Drug Delivery Systems: Entering the Mainstream Science 2004, 303, 1818-1822 (Pubitemid 38374867)
3. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an Emerging Platform for Cancer Therapy Nat. Nanotechnol. 2007, 2, 751-760 (Pubitemid 350223348)
4. Burgess, P.; Hutt, P. B.; Farokhzad, O. C.; Langer, R.; Minick, S.; Zale, S. On Firm Ground: IP Protection of Therapeutic Nanoparticles Nat. Biotechnol. 2010, 28, 1267-1270
5. Peer, D.; Park, E. J.; Morishita, Y.; Carman, C. V.; Shimaoka, M. Systemic Leucocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target Science 2008, 319, 627-630 (Pubitemid 351197066)
6. Ahmadvand, D.; Rahbarizadeh, F.; Moghimi, S. M. Biological Targeting and Innovative Therapeutic Interventions with Phage-Displayed Peptides and Structured Nucleic Acids (Aptamers). Curr. Opin. Biotechnol. 2011, DOI: 10.1016/j.copbio.2011.02.012.
7. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted Delivery of Cisplatin to Prostate Cancer Cells by Aptamer Functionalized Pt(IV) Prodrug-PLGA-PEG Nanoparticles Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 17356-17361
8. Blackstone, E. A.; Fuhr, J. P. Biosimilars and Innovation: An Analysis of the Possibility of Increased Competition in Biopharmaceuticals Future Med. Chem. 2010, 2, 1641-1649
9. Grabowski, H. Follow-on Biologics: Data Exclusivity and the Balance between Innovation and Competition Nat. Rev. Drug Discovery 2008, 7, 479-488 (Pubitemid 351767116)
10. Parmar, H. C. Biopharmaceuticals Market Overview. Pharm. Technol. Eur. 2006, March 1st.
11. Market Watch; Sales of Biologics to Show Robust Growth through to 2013. Nat. Rev. Drug Discovery 2009, 8, 837.
12. Akavia, U. D.; Litvin, O.; Kim, J.; Sanchez-Garcia, F.; Kotliar, D.; Causton, H. C.; Pochanard, P.; Mozes, E.; Garraway, L. A.; Péer, D. An Integrated Approach to Uncover Drivers of Cancer Cell 2010, 143, 1005-1017
13. Editorial. Making Data Dreams Come True. Nature 2004, 428, 239.
14. Petros, R. A.; DeSimone, J. M. Strategies in the Design of Nanoparticles for Therapeutic Applications Nat. Rev. Drug Discovery 2010, 9, 615-627
15. Kolishetti, N.; Dhar, S.; Valencia, P. M.; Lin, L. Q.; Karnik, R.; Lippard, S. J.; Langer, R.; Farokhzad, O. C. Engineering of Self-Assembled Nanoparticle Platform for Precisely Controlled Combination Drug Therapy Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 17939-17944
16. Swertz, M. A.; Jansen, R. C. Beyond Standardization: Dynamic Software Infrastructures for Systems Biology Nat. Rev. Genetics 2007, 8, 235-243
17. Semple, S. C.; Akinc, A.; Chen, J.; Sandhu, A. P.; Mui, B. L.; Cho, C. K.; Sah, D. W. Y.; Stebbing, D.; Crosley, E. J.; Yaworski, E. et al. Rational Design of Cationic Lipids for siRNA Delivery Nat. Biotechnol. 2010, 28, 172-176
18. Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking Down Barriers: Advances in siRNA Delivery Nat. Rev. Drug Discovery 2009, 8, 129-138
19. Pecot, C. V.; Calin, G. A.; Coleman, R. L.; Lopez-Berestein, G.; Sood, A. K. RNA Interference in the Clinic: Challenges and Future Directions Nat. Rev. Cancer 2011, 11, 59-67
20. Akthar, S.; Benter, I. F. Nonviral Delivery of Synthetic siRNA in Vivo J. Clin. Invest. 2007, 117, 3623-3632 (Pubitemid 350224068)
21. Kedmi, R.; Ben-Arie, N.; Peer, D. The Systemic Toxicity of Positively Charged Lipid Nanoparticles and the Role of Toll-Like Receptor 4 in Immune Activation Biomaterials 2010, 31, 6867-6875
22. Moghimi, S. M.; Symonds, P.; Murray, J. C.; Hunter, A. C.; Debska, G.; Szewczyk, A. A Two-Stage Poly(ethylenimine)-Mediated Cytotoxicity: Implications for Gene Transfer/Therapy Mol. Ther. 2005, 11, 990-995 (Pubitemid 40724119)
23. Szebeni, J.; Moghimi, S. M. Liposome Triggering of Innate Immune Responses: Perspective on Benefits and Adverse Reactions J. Liposome Res. 2009, 19, 85-90
24. Dobrovolskaia, M. A.; McNeil, A. E. Immunological Properties of Engineered Nanomaterials Nat. Nanotechnol. 2007, 2, 469-478 (Pubitemid 47220069)
25. Moghimi, S. M.; Hamad, I.; Andresen, T. L.; Jrgensen, K.; Szebeni, J. Methylation of the Phosphate Oxygen Moiety of Phospholipid-Methoxypoly(ethylene glycol) Conjugate Prevents PEGylated Liposome-Mediated Complement Activation and Anaphylatoxin Production FASEB J. 2006, 20, 2591-2593
26. Hamad, I.; Al-Hanbali, O.; Hunter, A. C.; Rutt, K. J.; Andresen, T. L.; Moghimi, S. M. Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at Nanosphere-Serum Interface: Implications for Stealth Nanoparticle Engineering ACS Nano 2010, 4, 6629-6638
27. Puzyn, T.; Rasulev, B.; Gajewicz, A.; Hu, X.; Dasari, T. P.; Michalkova, A.; Hwang, H.-M.; Toropov, A.; Leszczynska, D. Using Nano QSAR to Predict the Cytotoxicity of Metal Oxide Nanoparticles Nat. Nanotechnol. 2011, 6, 175-178
28. Moghimi, S. M.; Hunter, A. C.; Andresen, T. L. Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective. Annu. Rev. Pharmacol. Toxicol. 2012, DOI: 10.1146/annurev-pharmtox-010611-134623.
29. OECD; Health at a Glance: Europe 2010, OECD Publishing; http://dx.doi.org/10.1787/health-glance-2010-en; ISBN 978-92-64-09030-9 (print).